Anzeige
❌
Mehr »
Sonntag, 22.11.2026 - Börsentäglich über 12.000 News
Zufall oder Strategie? Copper One zündet die nächste Stufe seiner Kupfer-Offensive!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
05.11.T-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in tow
04.11.Charles River teams up with Ipsen to use virtual control groups in toxicology studies
04.11.nPhase rakes in $30M to expand AI-native clinical data platform
04.11.Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs
04.11.Minghui grants ASKA Japanese rights to sub-q TED candidate in $440M deal
04.11.Blackstone Life Sciences teams up with Boston Scientific in $455M heart pump deal
04.11.Smith+Nephew held failed talks with J&J over potential orthopedics combination
04.11.AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
04.11.Ultragenyx shrinks workforce and axes assets to halve R&D spend
04.11.Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
04.11.Novo's CEO still looking for deals to 'close some of the gaps,' as misfires hit profits
04.11.AbbVie invests £120M in UK, including new R&D headquarters
03.11.Abbott's Tectonic test looks to shift artery disease treatment with 'early' win
03.11.Rhythm doubles down on LG Chem obesity license, raising payout to as much as $855M
03.11.Philips sets aside $322M for proposed DOJ settlement over sleep apnea device recall
03.11.AbbVie abandons phase 2 solid tumor drug over 'limited benefit'
03.11.Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
03.11.BioArctic left out in the cold as Novartis walks away from $800M neuro collab
02.11.FDA grants uniQure's Huntington's gene therapy priority review, teeing up 'defining milestone'
02.11.OpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio for up to $91M
02.11.Teva ends trial of one of its original line-up of innovative meds over futility
02.11.FDA dims Bright Minds' outlook with partial hold on seizure trial over toxicity in mice
02.11.Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose struggles
02.11.China's InventisBio delivers competitive TYK2 data in phase 3 psoriasis win
30.10.Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials